pharma mar sa - PHMMF

PHMMF

Close Chg Chg %
92.19 3.81 4.13%

Closed Market

96.00

+3.81 (4.13%)

Volume: 5.50K

Last Updated:

Mar 31, 2026, 10:15 AM EDT

Company Overview: pharma mar sa - PHMMF

PHMMF Key Data

Open

$96.00

Day Range

96.00 - 96.00

52 Week Range

80.91 - 110.40

Market Cap

$1.67B

Shares Outstanding

17.36M

Public Float

12.11M

Beta

0.59

Rev. Per Employee

N/A

P/E Ratio

19.77

EPS

$4.98

Yield

88.89%

Dividend

$0.93

EX-DIVIDEND DATE

Jun 25, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

407.83

 

PHMMF Performance

1 Week
 
4.13%
 
1 Month
 
6.01%
 
3 Months
 
-0.72%
 
1 Year
 
170.96%
 
5 Years
 
N/A
 

PHMMF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About pharma mar sa - PHMMF

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.

PHMMF At a Glance

Pharma Mar SA
Avenida de los Reyes, 1
Colmenar Viejo, Madrid 28770
Phone 34-91-846-60-00 Revenue 249.86M
Industry Pharmaceuticals: Other Net Income 84.63M
Sector Health Technology 2025 Sales Growth 32.102%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

PHMMF Valuation

P/E Current 19.773
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.119
Price to Sales Ratio 6.145
Price to Book Ratio 5.163
Price to Cash Flow Ratio 25.60
Enterprise Value to EBITDA 25.628
Enterprise Value to Sales 5.591
Total Debt to Enterprise Value 0.042

PHMMF Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 3.511
Total Asset Turnover 0.604

PHMMF Liquidity

Current Ratio 3.019
Quick Ratio 2.443
Cash Ratio 1.781

PHMMF Profitability

Gross Margin 90.839
Operating Margin 18.192
Pretax Margin 26.944
Net Margin 33.871
Return on Assets 20.451
Return on Equity 33.089
Return on Total Capital 23.92
Return on Invested Capital 28.337

PHMMF Capital Structure

Total Debt to Total Equity 19.622
Total Debt to Total Capital 16.403
Total Debt to Total Assets 12.477
Long-Term Debt to Equity 14.566
Long-Term Debt to Total Capital 12.177
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pharma Mar Sa - PHMMF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
206.35M 170.98M 189.14M 249.86M
Sales Growth
-24.04% -17.14% +10.62% +32.10%
Cost of Goods Sold (COGS) incl D&A
18.18M 14.37M 16.18M 22.89M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.20M 6.22M 7.32M 9.05M
Depreciation
5.14M 5.11M 6.19M 8.65M
Amortization of Intangibles
1.06M 1.12M 1.14M 401.77K
COGS Growth
-22.34% -20.96% +12.56% +41.51%
Gross Income
188.17M 156.61M 172.96M 226.97M
Gross Income Growth
-24.20% -16.77% +10.44% +31.22%
Gross Profit Margin
+91.19% +91.60% +91.45% +90.84%
2022 2023 2024 2025 5-year trend
SG&A Expense
129.68M 148.58M 156.16M 165.99M
Research & Development
85.53M 104.87M 107.84M 104.94M
Other SG&A
44.15M 43.71M 48.33M 61.05M
SGA Growth
+1.08% +14.57% +5.11% +6.29%
Other Operating Expense
14.01M 13.82M 14.03M 15.52M
Unusual Expense
1.94M (292.98K) (234.73K) (1.33M)
EBIT after Unusual Expense
42.53M (5.49M) 3.01M 46.78M
Non Operating Income/Expense
5.99M 4.19M 12.63M 23.31M
Non-Operating Interest Income
919.60K 4.44M 6.14M 3.51M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.50M 2.61M 2.67M 2.78M
Interest Expense Growth
-37.37% +4.60% +2.25% +3.91%
Gross Interest Expense
2.50M 2.61M 2.67M 2.78M
Interest Capitalized
- - - -
-
Pretax Income
46.02M (3.92M) 12.96M 67.32M
Pretax Income Growth
-59.07% -108.51% +430.98% +419.29%
Pretax Margin
+22.30% -2.29% +6.85% +26.94%
Income Tax
(5.85M) (5.15M) (15.30M) (17.31M)
Income Tax - Current - Domestic
(2.48M) (4.14M) 435.92K (277.63K)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(3.37M) (1.00M) (15.73M) (17.03M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
51.87M 1.23M 28.26M 84.63M
Minority Interest Expense
- - - -
-
Net Income
51.87M 1.23M 28.26M 84.63M
Net Income Growth
-52.74% -97.63% +2,198.94% +199.47%
Net Margin Growth
+25.14% +0.72% +14.94% +33.87%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
51.87M 1.23M 28.26M 84.63M
Preferred Dividends
- - - -
-
Net Income Available to Common
51.87M 1.23M 28.26M 84.63M
EPS (Basic)
2.8738 0.0687 1.6112 4.855
EPS (Basic) Growth
-52.69% -97.61% +2,245.27% +201.33%
Basic Shares Outstanding
18.05M 17.90M 17.54M 17.43M
EPS (Diluted)
2.8717 0.0686 1.6091 4.8489
EPS (Diluted) Growth
-52.68% -97.61% +2,245.63% +201.34%
Diluted Shares Outstanding
18.06M 17.92M 17.56M 17.45M
EBITDA
50.67M 438.93K 10.10M 54.51M
EBITDA Growth
-55.32% -99.13% +2,200.50% +439.81%
EBITDA Margin
+24.56% +0.26% +5.34% +21.82%

Pharma Mar Sa in the News